<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did Acumen's operating expenses surge in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 01:13am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">The surge in Acumen Pharmaceuticals Inc's (ABOS) operating expenses in Q4 2024 can be attributed to **Increased Research and Development (R&amp;D) Expenses** and **General and Administrative (G&amp;A) Expenses**:

1. **Research and Development (R&amp;D) Expenses**: These rose to $93.8 million in 2024 from $42.3 million in 2023, primarily due to clinical trial costs and personnel expenses. The significant increase is attributed to the costs associated with the ALTITUDE-AD clinical trial.
2. **General and Administrative (G&amp;A) Expenses**: These rose to $20.2 million in 2024 from $18.8 million in 2023, driven by personnel costs.

In summary, the surge in operating expenses is a result of increased investments in R&amp;D and G&amp;A, reflecting the company's growth and expansion into new clinical trials and operational developments.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:F,comeFrom:"AInvestShareLink",events:[],answerSource:k}],fetch:{},error:l,state:{sharePreviewModule:{loadJgySuccess:m,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:k,cache_builder:a,reply_action:"Answer",execute_mode:w,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did Acumen's operating expenses surge in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did Acumen's operating expenses surge in Q4 2024?\",\"user_id\":\"dp60809050\",\"user_name\":\"\",\"trace_id\":\"df460c65-d0dd-4b46-9dd7-ba11829d7058\",\"session_id\":\"df460c65-d0dd-4b46-9dd7-ba11829d7058\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:r,title:G,summary:H,full_summary:"Financial Results and Business Highlights for the Year Ended December 31, 2024 Summary Cash Position: Cash, cash equivalents, and marketable securities totaled $231.5 million as of December 31, 2024, expected to support operations into the first half of 2027. Research and Development Expenses: Increased to $93.8 million in 2024 from $42.3 million in 2023, primarily due to clinical trial costs and personnel expenses. General and Administrative Expenses: Rose to $20.2 million in 2024 from $18.8 million in 2023, driven by personnel costs. Net Loss: Reported a net loss of $102.3 million for 2024, compared to a net loss of $52.4 million in 2023. Loss from Operations: Increased to $114.0 million in 2024 from $61.1 million in 2023, reflecting higher R&D and G&A expenses. On March 27, 2025, Acumen Pharmaceuticals Inc (ABOS, Financial) released its 8-K filing, detailing its financial results for the year ended December 31, 2024. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, with its lead drug candidate, ACU193, targeting amyloid-beta oligomers. Performance Overview and Challenges Acumen Pharmaceuticals Inc (ABOS, Financial) reported a net loss of $102.3 million for 2024, significantly wider than the $52.4 million net loss in 2023. This result translates to a net loss per share of $1.71, which is above the analyst estimate of -$1.55. The increased loss is primarily attributed to higher research and development (R&D) expenses, which rose to $93.8 million from $42.3 million in the previous year, driven by costs associated with the ALTITUDE-AD clinical trial. Financial Achievements and Industry Context Despite the increased losses, Acumen Pharmaceuticals Inc (ABOS, Financial) achieved significant milestones in its clinical development programs. The completion of enrollment for the Phase 2 ALTITUDE-AD study and positive Phase 1 results for a subcutaneous formulation of sabirnetug are critical steps f",url:I,image_url:a,video_url:a,publish_time:J,search_extra_info:{search_burial_info:{id:x,uid:K,ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]}}},simhash:"37c939376af41aca",msg_id:x}}],answer_chain_name:O,agent_mode:P,native_answer:a,come_from:a,text_answer:F,trace_id:e,cost:17548,event_names:a,question:d,fallback_type:Q,input_type:R,fall_back_reason:{fall_back_type:Q,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:3748,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:y,remote_svc:k,slots:[],answer_type:w,user_id:s,skill_name:z},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:s,question:d,source:k,raw_question:d,version:"3.4.1",action_name:z,nlu:{entity:[{type:S,value:"ABOS.O",market:T}]},output_time:y,deep_research:c,deep_thinking:c,agent_mode:P},extra:{}},{answer_path:g,section:{id:h,info_texts:["Thinking"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:g,section:{id:h,info_texts:["Querying Stock: ABOS Operating Expenses in Q4 2024"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:A},logs:[],extra:{action:U,action_input:"ABOS Operating Expenses in Q4 2024",thought:B}},{answer_path:g,section:{id:h,info_texts:["Querying Stock: ABOS Latest Report Period"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:A},logs:[],extra:{action:U,action_input:"ABOS Latest Report Period",thought:B}},{answer_path:g,section:{id:h,info_texts:["Searching Web: Acumen Operating Expenses Analysis in Q4 2024"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:A},logs:[],extra:{action:"Searching Web",action_input:"Acumen Operating Expenses Analysis in Q4 2024",thought:B}},{answer_path:f,section:{id:V,info_texts:[],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:V,info_texts:[],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:h,info_texts:["Generating Answer"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:t,info_texts:[],show_type:u,voice_txt:"The",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:u,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:I,image_url:a,video_url:a,title:G,summary:H,index:r,publish_time:J,search_id:x,search_uid:K,search_ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:t,info_texts:[],show_type:u,voice_txt:":\n\n1",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"ABOS",market_id:T,name:Y,domain:S},pos:13,section_id:t,txt:Y,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:t,info_texts:[],show_type:u,voice_txt:" and",text_answer:Z,rich_text:Z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:g,section:{id:h,info_texts:["Completed"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"ed4caa10ff3489f1b58aa19b7e4755ca",item_type:j,item_name:n,rec_info:_}},{display_text:o,query_text:o,trace_info:{item_id:"14bf61c09b803ec4743d1830e4050987",item_type:j,item_name:o,rec_info:$}},{display_text:p,query_text:p,trace_info:{item_id:"1eedd725195cd03c69ca2ad6dd71b4ab",item_type:j,item_name:p,rec_info:aa}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:m,type:"1",display2:c,url:a}},request_config:[{source_type:r,related_name:ab}],puuid:D,tag:a,category:"custom",uuid:ac}],global:{urp_static_data:[{name:ab,value:{status_code:m,columns:[{type:q,index_name:ad,key:ad},{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af},{type:q,index_name:ag,key:ag},{type:q,index_name:ah,key:ah}],datas:[{send_text:n,item_type:j,rec_info:_,display_text:n,rec_reason:a},{send_text:o,item_type:j,rec_info:$,display_text:o,rec_reason:a},{send_text:p,item_type:j,rec_info:aa,display_text:p,rec_reason:a}],dataSize:r,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ai,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:v,"min-height":"100%",position:aj,height:v},isMaterial:c,id:ai,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:m,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:E,componentUuid:ac,script:[{name:ak,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:E,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:E},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:v,position:aj,height:v},isMaterial:b,_id:19,id:ak,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:al,voice_txt:a,tracking_info:{},uuid:D},order:{is_auto:c,render_for:al,chart_type:"command",puuid:D}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:z,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:w,answer_chain_name:O},is_deep_research:c,deep_thinking:c,create_time:1746724404334},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:l,docsData:[],quoteData:l},tplType:"question"},events:am,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:am,client_ip:a,question:d,user_id:s,user_name:a,trace_id:e,session_id:e,source:k,input_type:R}}],userId:s,userName:a,startTime:y,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:l,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:m,traceTableData:l,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-acumens-operating-expenses-surge-in-q4-2024-49facf\u002F",config:{_app:{basePath:an,assetsPath:an,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"Why did Acumen's operating expenses surge in Q4 2024?","df460c65-d0dd-4b46-9dd7-ba11829d7058","other\u002FopenAnswer","progress\u002Fsearching_for",1000,"searching_for","llm_generated","ths_ainvest_lite_web",null,0,"💸 What is the impact of the surge in operating expenses on Acumen's profit margins and overall financial health?","🚀 Are there any recent announcements or developments that could explain the increase in operating expenses?","📈 How do analysts interpret the rise in operating expenses, and what are the potential implications for Acumen's stock price?","STR",3,"dp60809050",2001,"rich_text","auto","agent","d352f3dfd7375471_0",1746724386786,"inspect stocks","thinking","The user wants to analyze why Acumen's operating expenses increased significantly in Q4 2024. I should focus on the changes in operating expenses and their analysis in the latest report period. I will use FinQuery for the data mentioned above; use Search for the analysis in the latest report period.","signal","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","The surge in Acumen Pharmaceuticals Inc's (ABOS) operating expenses in Q4 2024 can be attributed to **Increased Research and Development (R&D) Expenses** and **General and Administrative (G&A) Expenses**:\n\n1. **Research and Development (R&D) Expenses**: These rose to $93.8 million in 2024 from $42.3 million in 2023, primarily due to clinical trial costs and personnel expenses. The significant increase is attributed to the costs associated with the ALTITUDE-AD clinical trial.\n2. **General and Administrative (G&A) Expenses**: These rose to $20.2 million in 2024 from $18.8 million in 2023, driven by personnel costs.\n\nIn summary, the surge in operating expenses is a result of increased investments in R&D and G&A, reflecting the company's growth and expansion into new clinical trials and operational developments.","Acumen Pharmaceuticals Inc (ABOS) Reports Q4 Net Loss Per Share of $1.71, Exceeding Analyst Estimate of -$1.55","Financial Results and Business Highlights for the Year Ended December 31, 2024 Summary Cash Position: Cash, cash equivalents, and marketable securities totaled $231.5 million as of December 31, 2024, expected to support operations into the first half of 2027. Research and Development Expenses: Incre...","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F2752977\u002Facumen-pharmaceuticals-inc-abos-reports-q4-net-loss-per-share-of-171-exceeding-analyst-estimate-of-155","2024-12-30","d352f3dfd7375471","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","185","Querying Stock",999,"The surge in Acumen Pharmaceuticals Inc's (ABOS) operating expenses in Q4 2024 can be attributed to **Increased Research and Development (R&D) Expenses** and **General and Administrative (G&A) Expenses**[^3]",":\n\n1. **Research","Acumen"," and Development (R&D) Expenses**: These rose to $93.8 million in 2024 from $42.3 million in 2023, primarily due to clinical trial costs and personnel expenses. The significant increase is attributed to the costs associated with the ALTITUDE-AD clinical trial[^3].\n2. **General and Administrative (G&A) Expenses**: These rose to $20.2 million in 2024 from $18.8 million in 2023, driven by personnel costs[^3].\n\nIn summary, the surge in operating expenses is a result of increased investments in R&D and G&A, reflecting the company's growth and expansion into new clinical trials and operational developments.","2+679_496_21_554+0+0+df460c65-d0dd-4b46-9dd7-ba11829d7058+ed4caa10ff3489f1b58aa19b7e4755ca+llm_generated+aimeTagAnalysis+0+0.011522804386913776+1","2+679_496_21_554+0+0+df460c65-d0dd-4b46-9dd7-ba11829d7058+14bf61c09b803ec4743d1830e4050987+llm_generated+aimeTagAnalysis+0+0.006430877838283777+2","2+679_496_21_554+0+0+df460c65-d0dd-4b46-9dd7-ba11829d7058+1eedd725195cd03c69ca2ad6dd71b4ab+llm_generated+aimeTagAnalysis+0+0.006219969131052494+3","recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>